May 12 |
Arcellx First Quarter 2024 Earnings: Beats Expectations
|
May 10 |
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
|
May 10 |
Arcellx GAAP EPS of -$0.14, revenue of $39.3M
|
May 10 |
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
|
May 9 |
Gilead's Kite, Arcellx share phase 3 trial design for CAR-T multiple myeloma asset
|
May 9 |
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
May 9 |
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
|
May 9 |
Arcellx Provides First Quarter 2024 Financial Results
|
May 9 |
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
|